247206-80-0

Basic information

• Product Name: 3-IODOBENZOYLACETONITRILE
• Synonyms: 3-IODOBENZOYLACETONITRILE;3-(3-IODO-PHENYL)-3-OXO-PROPIONITRILE;2-(3-Iodobenzoyl)acetonitrile
• CAS NO: 247206-80-0
• Molecular Formula: C₉H₆INO
• Molecular Weight: 271.05
• Mol File: 247206-80-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 391.2°C at 760 mmHg
• Flash Point: 190.4°C
• Appearance: /
• Density: 1.772g/cm³
• Vapor Pressure: 2.51E-06mmHg at 25°C
• Refractive Index: 1.62
• CAS DataBase Reference: 3-IODOBENZOYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODOBENZOYLACETONITRILE(247206-80-0)
• EPA Substance Registry System: 3-IODOBENZOYLACETONITRILE(247206-80-0)

Safety Data

• Hazardous Substances Data: 247206-80-0(Hazardous Substances Data)

Usage

General Description

3-Iodobenzoylacetonitrile is a chemical compound with the molecular formula C10H6INO. It is a yellow solid that is commonly used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. 3-Iodobenzoylacetonitrile is primarily used in the production of a wide range of fine chemicals, including active pharmaceutical ingredients and intermediates. It is also utilized in the synthesis of organic compounds and materials. Additionally, 3-Iodobenzoylacetonitrile is an important building block in the development of new chemical and pharmaceutical products, making it a valuable resource in the chemical industry.

InChI:InChI=1/C9H6INO/c10-8-3-1-2-7(6-8)9(12)4-5-11/h1-3,6H,4H2

Upstream product

• 58313-23-8 3-iodobenzoic acid methyl ester 
• 75-05-8 acetonitrile 
• 1711-10-0 3-iodobenzoyl chloride 
• 372-09-8 cyanoacetic acid 
• 618-51-9 3-Iodobenzoic acid 
• 51934-41-9 4-iodobenzoic acid ethyl ester 

Downstream Products

• 938163-41-8 2-bromo-3-(3-iodophenyl)-3-oxopropanamide 
• 249937-44-8 [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-(3-vinylphenyl)methanone 
• 249937-23-3 5-amino-1-(4-fluorophenyl)-4-(3-iodobenzoyl)pyrazole 
• 882175-35-1 [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(1-benzyloxymethylvinyl)phenyl]methanone 
• 882175-39-5 [5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2-benzyloxy-1-hydroxy-1-hydroxymethylethyl)phenyl]methanone 
• 1217089-18-3 C₉H₈IN₃ 

Relevant articles and documents

Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors

Described herein is design, synthesis, and biological evaluation of novel series of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines acting as inhibitors of type 4 phosphodiesterase (PDE4) which is known as a good target for the treatment of asthma and COPD. For this purpose, structure optimization was conducted with the aid of structure-based drug design using the known X-ray crystallography. Also, biological effects of these compounds on the target enzyme were evaluated by using in vitro assays, leading to the potent and selective PDE-4 inhibitor (IC50 10 nM).

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3- dihydroxypropoxy)phenyl]-methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 Map kinase

A novel class of highly selective inhibitors of p38 MAP kinase was discovered from high throughput screening. The synthesis and optimization of a series of 5-amino-N-phenyl-1H-pyrazol-4-yl-3-phenylmethanones is described. An X-ray crystal structure of this series bound in the ATP binding pocket of unphosphorylated p38a established the presence of a unique hydrogen bond between the exocyclic amine of the inhibitor and threonine 106 which likely contributes to the selectivity for p38. The crystallographic information was used to optimize the potency and physicochemical properties of the series. The incorporation of the 2,3-dihydroxypropoxy moiety on the pyrazole scaffold resulted in a compound with excellent drug-like properties including high oral bioavailability. These efforts identified 63 (RO3201195) as an orally bioavailable and highly selective inhibitor of p38 which was selected for advancement into Phase I clinical trials.